DUBLIN – Step Pharma SAS closed a €35 million (US$41.5 million) series B round to move its first-in-class cytidine triphosphate synthase 1 inhibitor into clinical trials in patients with T-cell and B-cell malignancies.
HONG KONG – Bispecific antibody startup Epimab Biotherapeutics Inc. has completed a $120 million series C financing, bringing it closer to a potential IPO next year. The Shanghai-based company said the new funds would help it move EMB-01 into phase II testing this year.
While historical data suggest venture capital rounds will eventually dip below the peak years, biopharma financings completed in recent months indicate the dollars are continuing to climb in 2021. A maturing industry, the high potential of cell and gene therapy products, the advancing technologies of artificial intelligence and machine learning, as well as an eager financial community, are all responsible for the ever-increasing availability of private money.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Beigene, Boston Immune Technologies and Therapeutics, Connect, I-Mab, Innoforce, Neoimmunetech, Noxopharm, Nyrada, Tavotek.
Asher Biotherapeutics Inc. raised $55 million in a series A financing round to take forward a series of engineered cytokines designed to selectively activate T cells or other immune effector cells, in order to eliminate both the toxicities and the loss of efficacy that can result from indiscriminate activation.
HONG KONG - Bispecific antibody startup Epimab Biotherapeutics Inc. has completed a $120 million series C financing, bringing it closer to a potential IPO next year. The Shanghai-based company said the new funds would help it move its EGFR/cMET-targeted bispecific candidate, EMB-01, into phase II testing this year, as well supporting the advancement of other clinical candidates and an expansion of its pipeline.
PERTH, Australia – With a fresh injection of A$28.9 million (US$22.4 million) in grant funding from the Australian government and a capital raise of A$40 million, 4dmedical Ltd. is well on its way to commercializing its first lung imaging product in the U.S. and Australia. 4dmedical’s X-ray velocimetry (XV) technology is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.
RSS
